425: Kintara Therapeutics and TuHURA Biosciences Announce Definitive Merger Agreement, Creating Phase 3 Immuno-Oncology Company

Kintara Therapeutics and TuHURA Biosciences have entered into a definitive merger agreement to form a company focused on advancing novel technologies to overcome resistance to cancer immunotherapy.

Summary

• Kintara Therapeutics and TuHURA Biosciences have agreed to merge in an all-stock transaction.
• The combined company will focus on advancing TuHURA's personalized cancer vaccine and first-in-class bi-functional Antibody Drug Conjugates (ADCs).
• TuHURA's lead program, IFx-2.0, is expected to enter a Phase 3 trial as adjunctive therapy with Keytruda for advanced Merkel cell carcinoma in the second half of 2024.
• TuHURA has a $31 million subscribed financing in connection with the merger agreement, expected to provide cash runway into late 2025.
• Post-merger, Kintara equityholders are expected to own approximately 2.85% (or 5.45% including CVR shares) and TuHURA equityholders are expected to own approximately 97.15% (or 94.55% including CVR shares) of the combined company on a pro forma fully diluted basis.
• Kintara stockholders will receive Contingent Value Rights (CVRs) entitling them to shares of Kintara common stock upon achievement of a milestone related to a REM-001 study.
• The merger is expected to close in the third quarter of 2024, with the combined company operating as TuHURA Biosciences, Inc. under the ticker HURA.
• The board of directors of the combined company will be composed of five members, with four designated by TuHURA and one by Kintara.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the merger, highlighting the potential for value creation and the advancement of innovative cancer therapies. The focus on Phase 3 development and the $31 million financing contribute to a favorable sentiment.

Positives

• The merger creates a Phase 3 clinical-stage company with a risk-diversified pipeline.
• TuHURA's technologies target key areas in immuno-oncology, including personalized cancer vaccines and ADCs.
• The $31 million subscribed financing provides a cash runway into late 2025.
• Kintara stockholders have the potential to receive additional shares through CVRs upon achievement of a REM-001 study milestone.

Negatives

• Kintara equityholders will have a small ownership stake in the combined company (2.85% or 5.45% including CVR shares).
• The success of the combined company depends on the successful development and commercialization of TuHURA's technologies.
• The CVRs are contingent and may not result in any additional value for Kintara stockholders.

Risks

• The merger is subject to stockholder approval and other customary closing conditions.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The combined company may face competition from other companies in the immuno-oncology space.
• The combined company may require additional financing in the future.

Future Outlook

The combined company will focus on advancing TuHURA's personalized cancer vaccine and first-in-class bi-functional ADCs, with a Phase 3 trial for IFx-2.0 expected to begin in the second half of 2024. The company expects to have a cash runway into late 2025.

Management Comments

• Robert E. Hoffman: 'Merging with TuHURA represents the best path forward for our stockholders and has the potential to deliver near and long-term value.'
• Dr. James Bianco: 'This proposed merger with Kintara lets us achieve that goal while combining the resources of the two companies.'

Industry Context

The announcement reflects a trend in the biopharmaceutical industry towards consolidation and specialization, with companies seeking to build stronger pipelines and expertise in specific therapeutic areas like immuno-oncology. The focus on overcoming resistance to immunotherapy is a key area of unmet need and innovation in the cancer treatment landscape.

Comparison to Industry Standards

• The merger aims to create a company comparable to other Phase 3 clinical-stage immuno-oncology companies.
• TuHURA's approach of targeting MDSCs with bi-functional ADCs is a novel strategy compared to traditional ADCs that target tumor cells directly.
• The reliance on the FDA's Accelerated Approval Pathway is a common strategy for companies developing therapies for serious conditions with unmet medical needs, similar to companies like Immunocore and Seagen.
• The $31 million subscribed financing is intended to provide a cash runway comparable to other similar-stage biotech companies, such as Iovance Biotherapeutics and Adaptimmune Therapeutics.

Management Changes

Corporate Governance

Legal Proceedings

• The document mentions the potential for legal proceedings related to the merger agreement or the transactions contemplated thereby.

Stakeholder Impact

• Kintara stockholders have the potential to benefit from the value creation of the combined company and the CVRs.
• TuHURA stockholders will gain access to the public markets and additional resources to advance their pipeline.
• Patients with cancer may benefit from the development of new and innovative therapies.
• Employees of both companies may be affected by the integration of the two organizations.

Next Steps

• Obtain stockholder approval from both Kintara and TuHURA.
• Close the merger transaction, expected in the third quarter of 2024.
• Initiate the Phase 3 trial for IFx-2.0 in Merkel cell carcinoma in the second half of 2024.
• Advance the development of TuHURA's bi-functional ADCs and IFx-3.0 program.

Key Dates